Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), relating to its proposed sale to Assertio Holdings, Inc. Under the terms of the agreement, SPPI shareholders are expected to receive 0.1783 shares of Assertio common stock and one CVR worth up to $0.20, based upon the 2024 and 2025 net sales of ROLVEDON, per share they own.